Immorta Bio Presents SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting

PR Newswire
May 5, 2025

Immorta Bio was selected to present alongside Pfizer and the University of Pittsburgh at the 2025 American Association of Immunologists Annual Meeting in Honolulu. The company unveiled new data on SenoVax™, its first-in-class senolytic immunotherapy that trains the immune system to target senescent cells—offering a novel approach to treating both cancer and aging.

‍

‍

Read Full Article

Never Miss A Headline

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By subscribing, you are acknowledging your consent to receive  Immorta Bio newsletters

Explore More

September 23, 2026

Immorta Bio Selected for NYU Stern's Endless Frontier Labs 2026-27 Life Sciences Cohort

Read more
June 9, 2026

Immorta Bio Discusses its AI-Enabled Personalized Therapeutic Paradigm for Restoring Youthful Biology at Leading Global Biotech Forum

Read more
May 21, 2026

Scientific Longevity Company Immorta Bio Appoints Former Ernst & Young Health Sciences Partner Howard Brooks to Corporate Board of Directors

Read more
See all news
Mailing 7064 Fisher Island Drive, Miami Beach, Florida 33109
Office: 19505 Biscayne Blvd, Ste 2350 Aventura, Florida 33180
305 632-2939
support@immortabio.com
Social Media
Science
Science of Aging
SenoVax™
StemCell Revivify™
Intellectual Property
Publications
Pipeline
Main Pipeline
About Us
Mission
People
Careers
News
Investors
Contact Us
Copyright © Immorta Bio, Inc | All Rights Reserved
Privacy Policy

Cookie Settings

We use cookies and similar technologies to help personalise content, tailor and measure ads, and provide a better experience. By clicking OK or turning an option on in Cookie Preferences, you agree to this, as outlined in our cookie Policy.

Allow AllReject